To further validate these findings, it will be important to determine if the presence of mutant p53R175H, p53R273H, or p53R280K and/or overexpression of STMN1 are associated with chemoresistance in patients with colon and breast cancer; if this association is confirmed, it might be a valuable chemoresistance prognostic factor (Figure 4B; Table 1). This evidence concerns the gene STMN1 and breast cancer.